Inspyr Therapeutics, Inc. (NSPX) financial statements (2021 and earlier)

Company profile

Business Address 2629 TOWNSGATE RD, SUITE 215
WESTLAKE VILLAGE, CA 91361
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000122
Cash and cash equivalents0000122
Restricted cash and investments 00    
Prepaid expense   0000
Total current assets:0000133
Noncurrent Assets
Property, plant and equipment (0)00000
Intangible assets, net (including goodwill) (0)00000
Intangible assets, net (excluding goodwill) (0)00000
Other undisclosed noncurrent assets 0  000
Total noncurrent assets:  00000
TOTAL ASSETS:0000133
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4444234
Accounts payable2222111
Accrued liabilities2222021
Employee-related liabilities      1
Debt2332  0
Derivative instruments and hedges, liabilities722331 
Other undisclosed current liabilities      (1)
Total current liabilities:13999453
Noncurrent Liabilities
Total liabilities:13999453
Stockholders' equity
Stockholders' equity attributable to parent, including:(13)(9)(8)(9)(3)(2)0
Common stock0000 00
Additional paid in capital54525151454339
Accumulated deficit(67)(61)(60)(60)(49)(45) 
Other undisclosed stockholders' equity attributable to parent      (39)
Total stockholders' equity:(13)(9)(8)(9)(3)(2)0
TOTAL LIABILITIES AND EQUITY:0000133

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(2)(1)(1)(6)(3)(6)(7)
Operating loss:(2)(1)(1)(6)(3)(6)(7)
Interest and debt expense0000  0
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(4)(0)1(5)(0)0 
Net loss attributable to parent:(6)(1)(0)(11)(4)(6)(7)
Preferred stock dividends and other adjustments00(0)(2)   
Other undisclosed net loss available to common stockholders, basic(0)(0)     
Net loss available to common stockholders, diluted:(6)(1)(0)(13)(4)(6)(7)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(6)(1)(0)(11)(4)(6)(7)
Comprehensive loss, net of tax, attributable to parent:(6)(1)(0)(11)(4)(6)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: